Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000;49 Suppl 1(Suppl 1):61S-64S.
doi: 10.1046/j.1365-2125.2000.00155.x.

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

G Apseloff  1 , D Mullet, K D Wilner, R J Anziano, T G Tensfeldt, S M Pelletier, N Gerber
Affiliations
Clinical Trial

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

G Apseloff et al. Br J Clin Pharmacol. 2000.

Abstract

Aims: To assess the potential of ziprasidone to alter the renal clearance and steady-state serum levels of lithium.

Methods: Healthy subjects who had stable serum lithium levels during the first 7 days of treatment with lithium 900 mg day(-1), given as two divided daily doses, were randomized to receive concomitant treatment with either ziprasidone, 40 mg day(-1), given as two divided daily doses, on days 9-11 followed by 80 mg day(-1), given as two divided daily doses on days 12-15 (n = 12), or placebo twice daily (n = 13). Ziprasidone or placebo was administered 2 h before each dose of lithium.

Results: Ziprasidone administration was associated with a 0.07 mmol l(-1) (13%) mean increase in steady-state serum lithium levels compared with a mean increase of 0.06 mmol l(-1) (10%) with placebo. Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group. None of these differences between the two groups was statistically or clinically significant.

Conclusions: Ziprasidone does not alter steady-state serum lithium concentrations or renal clearance of lithium.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma concentration–time curves for serum lithium at the end of monotherapy (day 8, ––––) and at the end of combination therapy (day 15, ----) with ziprasidone 40–80 mg day−1 (a) or placebo (b).
See this image and copyright information in PMC

References

    1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gulman AG, Molinoff PB, Ruddon RW, Hardman JG, Limbird LE, editors. The Pharmacological Basis of Therapeutics. 9. New York: McGraw-Hill; pp. 431–459.
    1. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29:172–191. - PubMed
    1. Siris SG. Pharmacological treatment of depression in schizophrenia. In: Delisi LE, editor. Depression in Schizophrenia. Washington, DC: American Psychiatric Press; 1990. pp. 141–162.
    1. Keck Pe, Jr, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacol Berl. 1994;114:529–538. - PubMed
    1. Kimmmel S, Calabrese JR, Woyshville MJ, et al. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry. 1994;55(Suppl B):91–93. - PubMed

Publication types

LinkOut - more resources